NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Finnrick
Free Test
← PT-141 vendors

NexaphPT-141

3 testslatest 28 Apr 2026
Visit websitenexaph.comIntelligence report31 pages · who runs this vendorMonitor this vendor24/7 safety alerts · Finnrick Gold
Free peptide testing

Ordered PT-141 from Nexaph? Mail in a sample (US only) and let us test it for free.

Test my supply
+5 more ↓
71%
Finnrick rating
#10 of 44 PT-141 vendors
3 of 3 classifiable tests passed
natural 100% · customers 5.0★ (1)
methodology · Purity focus
Finnrick analysis · PT-141

Nexaph's strongest purity-focus evidence is in GHK-Cu, with Retatrutide and Tirzepatide improving recently after earlier purity and fill outliers. The record is dispersed: Semaglutide, Tesamorelin, and CJC-1295 remain weak from repeated purity or identity/quantity failures, and batch-ID gaps temper an otherwise current, high-volume dataset.

methodology →
vendor intelligence report
Vendor Intelligence Report: Nexaph

Corporate records, RDAP data and site emails trace Nexaph through a fragmented operator identity rather than a clean public counterparty. The report maps sister-brand infrastructure, COA-cloning pathways and a certification/payment layer that changes buyer recourse.

31 pages8 risk factors assessed3 Jul 2026
read the report
Peptides
14 rated · tap to focus
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.25
89%
11
2
Tirzepatide
$1.13
76%
62
3
Retatrutide
$2.46
74%
103
4
PT-141selected
-
71%
3
5
Ipamorelin
$1.30
60%
10
6
BPC-157
$1.51
60%
19
7
Cagrilintide
$3.50
50%
13
8
TB-500
$1.61
38%
6
9
Tesamorelin
$2.88
37%
30
10
Sermorelin
-
37%
3
11
Semaglutide
$1.90
36%
15
12
CJC-1295
$2.78
30%
8
13
NAD+
$0.04
28%
3
14
MOTS-c
$1.88
23%
5
Contact channels
2 channels on file
Websitenexaph.comEmailcain@nexaph.com
Rating trend
PT-141 from this vendor, after each test
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%10 Sept 2025: 57%20 Feb 2026: 67%28 Apr 2026: 70%29 Sept 2026: current 71%57%67%71%Sep 25Sep 26
Showing PT-141 tests only
Nexaph PT-141 test history
3 tests · 3 pass · 0 fail
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
28 Apr 2026Pass
uryr26h
Tested
lab nameView COA
20 Feb 2026Pass
f35zxjy
Tested
lab nameView COA
10 Sep 2025Pass
fx68pdv
Tested
lab nameView COA

About Nexaph test results from Finnrick

Nexaph is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 14 peptides and 291 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible Nexaph peptides in this dataset are BPC-157 (19 tests) and Semaglutide (15 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 200 recent tests.

Corrections
0 corrections
No corrections.
Free peptide testing

Ordered PT-141 from Nexaph? Mail in a sample (US only) and let us test it for free.

Test my supply